Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Treg gene signatures predict and measure type 1 diabetes trajectory
Anne M. Pesenacker, … , Scott J. Tebbutt, Megan K. Levings
Anne M. Pesenacker, … , Scott J. Tebbutt, Megan K. Levings
Published February 7, 2019
Citation Information: JCI Insight. 2019;4(6):e123879. https://doi.org/10.1172/jci.insight.123879.
View: Text | PDF
Clinical Research and Public Health Endocrinology Immunology

Treg gene signatures predict and measure type 1 diabetes trajectory

  • Text
  • PDF
Abstract

BACKGROUND. Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that, compared with healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting that this could be an immunoregulatory biomarker. METHODS. nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or peripheral blood mononuclear cells (PBMCs) from individuals with T1D or type 2 diabetes, healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were developed and applied to various sample group comparisons. RESULTS. Compared with controls, the TGS in isolated Tregs or PBMCs was altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity or specificity of biomarkers increased by including T1D-associated SNPs in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (αIL-12/23p40) for future rapid versus slow C-peptide decline. CONCLUSION. These data suggest that biomarkers based on measuring TGSs could be a new approach to stratify patients and monitor autoimmune activity in T1D. FUNDING. JDRF (1-PNF-2015-113-Q-R, 2-PAR-2015-123-Q-R, 3-SRA-2016-209-Q-R, 3-PDF-2014-217-A-N), the JDRF Canadian Clinical Trials Network, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI109565 and FY15ITN168), and BCCHRI.

Authors

Anne M. Pesenacker, Virginia Chen, Jana Gillies, Cate Speake, Ashish K. Marwaha, Annika Sun, Samuel Chow, Rusung Tan, Thomas Elliott, Jan P. Dutz, Scott J. Tebbutt, Megan K. Levings

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2019 Total
Citations: 3 3 5 5 5 2 23
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2025 (3)

Title and authors Publication Year
Genetics of circulating proteins in newborn babies at high risk of type 1 diabetes
Tutino M, Yu NY, Hatzikotoulas K, Park YC, Kreitmaier P, Katsoula G, Berner R, Casteels K, Elding Larsson H, Kordonouri O, Ołtarzewski M, Szypowska A, Ott R, Weiss A, Winkler C, Zapardiel-Gonzalo J, Petrera A, Hauck SM, Bonifacio E, Ziegler AG, Zeggini E
Nature Communications 2025
Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset
Golden GJ, Wu VH, Hamilton JT, Amses KR, Shapiro MR, Sada Japp A, Liu C, Pampena MB, Kuri-Cervantes L, Knox JJ, Gardner JS, Atkinson MA, Brusko TM, Luning Prak ET, Kaestner KH, Naji A, Betts MR
Nature Communications 2025
Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function
Boardman DA, Mangat S, Gillies JK, Leon L, Fung VC, Haque M, Mojibian M, Halvorson T, Huang Q, Tuomela K, Wardell CM, Brown A, Lam AJ, Levings MK
Science Advances 2025

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts